



**Company Contact:**  
**Richard Gabriel**  
**CEO and President**  
**941 366-3400**

**-or-**

**Ron Stabiner**  
**The Wall Street Group, Inc.**  
**212-888-4848**

**FOR IMMEDIATE RELEASE:**

**DNAPRINT GENOMICS ANCESTRY TECHNOLOGY HIGHLIGHTED  
IN ARTICLE IN THE NEW YORK TIMES**

**SARASOTA, Fla., April 13, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG)** today announced that the Company's technology was highlighted in an article entitled "Seeking Ancestry in DNA Ties Uncovered by Tests" in the April 12, 2006 edition of The New York Times.

The article reported that genetic tests, once obscure tools for scientists, have begun to influence everyday lives in many ways and that people are utilizing them when applying for jobs and college scholarships. "The tests are reshaping people's sense of themselves – where they come from, why they behave as they do, what disease might be coming their way," The Times reported.

Commenting on the article following its publication, DNAPrint President and Chief Executive Officer Richard Gabriel said that there is a growing interest and demand for the Company's ANCESTRYbyDNA™ technology for determining family heritage. "In many instances, people who take the test want to determine whether they have American Indian or other ancestry to validate eligibility for college admission or scholarship programs. DNAPrint Genomics maintains the largest Native American DNA Database in North America."

In addition to its ANCESTRYbyDNA™ test for determining family heritage, DNAPrint Genomics' technology has forensic applications. The Company's DNAWITNESS™ product analyzes DNA taken from crime scenes, and has been utilized in more than 100 criminal investigations worldwide. DNAWITNESS™ test results have assisted investigators in many high profile criminal cases, including the apprehension and conviction of a serial killer in Louisiana.

The article can be accessed on the newspaper's web site at <http://www.nytimes.com/2006/04/12/us/12genes.html?ei=5094&en=7cb857e4ae15fb91&hp=&ex=1144900800&adxnnl=1&partner=homepage&adxnnlx=1144819973-wXIVt3CajOnkY/qwBw5LOg>.

**About DNAPrint Genomics, Inc.**

DNAPrint Genomics, Inc. ([www.dnaprint.com](http://www.dnaprint.com)) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials

(MORE)

to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to [www.dnaprint.com](http://www.dnaprint.com) for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

### **Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###